JAAD Mendeley Supplemental: Female sex is associated with higher rates of dermatologic adverse events among patients with melanoma receiving immune checkpoint inhibitor therapy: a retrospective cohort study

Published: 9 March 2021| Version 2 | DOI: 10.17632/7psyyvctb6.2
Contributor:
Ai-Tram Bui

Description

JAAD Research Letter Supplemental Figure: Female sex is associated with higher rates of dermatologic adverse events among patients with melanoma receiving immune checkpoint inhibitor therapy: a retrospective cohort study

Files